Basic Information
INTRAGAM P INJECTION 6% w/v
INJECTION
Regulatory Information
SIN12022P
July 15, 2002
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XJ06BA02
Company Information
CSL Behring (Australia) Pty Ltd
BLOOD SERVICES GROUP, HEALTH SCIENCES AUTHORITY
BLOOD SERVICES GROUP, HEALTH SCIENCES AUTHORITY
Active Ingredients
Strength: 6 g/100 mL
Detailed Information
Contraindications
**CONTRAINDICATIONS** Intragam P is contraindicated in patients: - Who have had a true anaphylactic reaction to a human immunoglobulin preparation - Who are IgA-deficient with antibodies to IgA and a history of hypersensitivity - With a history of hypersensitivity to the excipient maltose.
Indication Information
**INDICATIONS** Intragam® P is indicated for replacement IgG therapy in: - primary immunodeficiency - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. Intragam® P is indicated for immunomodulatory therapy in: - Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - Kawasaki disease. Comprehensive evidence-based guidelines describing appropriate clinical use of intravenous immunoglobulin in ITP have been published and should be followed wherever possible to avoid the inappropriate utilisation of this blood product1, 2. * * * **REFERENCES** 1. George, JN _et al_: Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology. Blood 88, 3–40, 1996. 2. The American Society of Hematology ITP Guideline Panel: Diagnosis and Treatment of Idiopathic Thrombocytopenic Purpura: Recommendations of The American Society of Hematology. Ann Intern Med 126, 319–326, 1997.